LawPlayer
My bookmarks
Source

2011/785/EU: Commission Implementing Decision of 28 November 2011 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2011) 7382) Text with EEA relevance

2011/785/EU: Commission Implementing Decision of 28 November 2011 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2011) 7382) Text with EEA relevance

Decision 2008/911/EC · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annexes I and II of Decision 2008/911/EC are amended in accordance with the Annex to this Decision.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Annexes I and II to Decision 2008/911/EC are amended as follows: 1. in Annex I, the following substance is inserted after Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (sweet fennel fruit): ‘ Hamamelis virginiana L., folium et cortex aut ramunculus destillatum ’; 2. in Annex II, the following is inserted after the entry relating to Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus: ‘ COMMUNITY LIST ENTRY ON HAMAMELIS VIRGINIANA L., FOLIUM ET CORTEX AUT RAMUNCULUS DESTILLATUM Scientific name of the plant Hamamelis virginiana L. Botanical family Hamamelidaceae Herbal preparation(s) 1. Distillate prepared from fresh leaves and bark (1:1.12 – 2.08; extraction solvent ethanol 6 % m/m) 2. Distillate prepared from dried twigs (1:2; extraction solvent ethanol 14-15 %)  ( *1 ) European pharmacopoeia monograph reference Not applicable Indication(s) Indication (a) Traditional herbal medicinal product for relief of minor skin inflammation and dryness of the skin. Indication (b) Traditional herbal medicinal product to be used for the temporary relief of eye discomfort due to dryness of the eye or to exposure to wind or sun. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. Type of tradition European Specified strength Please see ‘Specified posology’. Specified posology Children over six years of age, adolescents, adults and elderly Indication (a) Distillate in a strength corresponding to 5-30 % in semi-solid preparations, several times daily. The use in children under six years of age is not recommended (see section ‘Special warnings and precautions for use’). Adolescents, adults and elderly Indication (b) Eye drops  ( *2 ) Distillate (2) diluted (1:10), 2 drops/each eye, 3-6 times daily. The use in children under 12 years of age is not recommended (see section ‘Special warnings and precautions for use’). Route of administration   Cutaneous use.   Ocular use. Duration of use or any restrictions on the duration of use Children over six years of age, adolescents, adults and elderly Indication (a) If the symptoms persist longer than two weeks during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted. Adolescents, adults and elderly Indication (b) The recommended duration of use is four days. If the symptoms persist longer than two days during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance. Special warnings and precautions for use Indication (a) The use in children under six years of age has not been established due to lack of adequate data. Indication (b) If eye pain, changes in vision, continued redness, or irritation of the eye is experienced, or if the condition worsens or persists for more than 48 hours during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted. The use in children under 12 years of age has not been established due to lack of adequate data. For extracts containing ethanol, the appropriate labelling for ethanol, taken from the ‘Guideline on excipients in the label and package leaflet of medicinal products for human use’, must be included. Interactions with other medicinal products and other forms of interaction None reported. Pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Indication (a) Allergic contact dermatitis may occur in sensitive patients. The frequency is not known. Indication (b) Conjunctivitis cases have been reported. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars [if necessary] Not applicable. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [if necessary for the safe use of the product] Not applicable. ( *1 )   According to USP (USP-31- NF 26, 2008 Vol 3:3526)." ( *2 )   The medicinal product complies with the Ph. Eur. monograph on eye preparations (01/2008:1163).’." ( *1 )   According to USP (USP-31- NF 26, 2008 Vol 3:3526). ( *2 )   The medicinal product complies with the Ph. Eur. monograph on eye preparations (01/2008:1163).’.’

Other acts of the same type
Commission Implementing Decision (EU) 2017/2334 of 14 December 2017 postponing the expiry date of approval of creosote for use in biocidal products of product-type 8 (Text with EEA relevance. )Commission Implementing Decision (EU) 2017/2353 of 14 December 2017 authorising the placing on the market of oil from Calanus finmarchicus as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 8426)Commission Implementing Decision (EU) 2017/2354 of 14 December 2017 authorising an extension of use of Chia seeds (Salvia hispanica) as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 8470)Commission Implementing Decision (EU) 2017/2355 of 14 December 2017 authorising the placing on the market of UV-treated mushrooms as a novel food under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 8474)Commission Implementing Decision (EU) 2017/2373 of 14 December 2017 authorising the placing on the market of hydroxytyrosol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document number C(2017) 8423)Commission Implementing Decision (EU) 2017/2318 of 13 December 2017 on the equivalence of the legal and supervisory framework in Australia applicable to financial markets in accordance with Directive 2014/65/EU of the European Parliament and of the Council (Text with EEA relevance. )Commission Implementing Decision (EU) 2017/2319 of 13 December 2017 on the equivalence of the legal and supervisory framework applicable to recognised exchange companies in Hong Kong Special Administrative Region in accordance with Directive 2014/65/EU of the European Parliament and of the Council (Text with EEA relevance. )Commission Implementing Decision (EU) 2017/2320 of 13 December 2017 on the equivalence of the legal and supervisory framework of the United States of America for national securities exchanges and alternative trading systems in accordance with Directive 2014/65/EU of the European Parliament and of the Council (Text with EEA relevance. )Council Decision (CFSP) 2017/2302 of 12 December 2017 in support of the OPCW activities to assist clean-up operations at the former chemical weapons storage site in Libya in the framework of the implementation of the EU Strategy against Proliferation of Weapons of Mass DestructionCouncil Decision (CFSP) 2017/2303 of 12 December 2017 in support of the continued implementation of UN Security Council Resolution 2118 (2013) and OPCW Executive Council decision EC-M-33/DEC.1 on the destruction of Syrian chemical weapons, in the framework of the implementation of the EU Strategy against proliferation of weapons of mass destructionCommission Implementing Decision (EU) 2017/2316 of 12 December 2017 repealing Decision 92/176/EEC concerning maps to be provided for use for the Animo network (notified under document C(2017) 8316) (Text with EEA relevance. )Decision (EU) 2017/2380 of the European Parliament and of the Council of 12 December 2017 amending Directive 2010/40/EU as regards the period for adopting delegated acts (Text with EEA relevance. )

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next